Melanotan I

Overview

Melanotan I is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring signaling peptide that regulates skin pigmentation. It is designed to stimulate the body’s own production of melanin, and is most often discussed in the context of tanning and photoprotection.

Unlike most peptides in this reference, Melanotan I has a regulated, approved form. As afamelanotide (brand name Scenesse), it is delivered as a subcutaneous implant and is FDA-approved to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP), a rare condition marked by painful skin reactions to light. This approval followed randomized controlled trials in EPP patients.

It is important to separate that approved implant from the injectable “Melanotan I” sold through the research-chemical market for cosmetic tanning. Those products are unapproved, and their purity and contents are not verified.

How it works

Melanotan I is a linear 13-amino-acid peptide that selectively activates the melanocortin-1 receptor (MC1R) on melanocytes, the pigment-producing cells in the skin. Activating MC1R promotes the synthesis of eumelanin, the darker form of melanin, which can help absorb and dissipate light.

In erythropoietic protoporphyria, this increase in melanin is thought to reduce phototoxic reactions by shielding the skin from the light that triggers them. Compared with Melanotan II, Melanotan I is generally described as more receptor-selective, which is often cited as a reason for its comparatively milder reported effects.

Reported benefits

• Increased skin pigmentation / tanning response (the effect it is studied for)
• Reduced light-triggered pain in erythropoietic protoporphyria (the FDA-approved implant indication)
• A milder side-effect profile than commonly reported for Melanotan II

These reflect reported and studied effects and are not guaranteed outcomes; the cosmetic tanning use of injectable Melanotan I has not been established as safe or effective.

Considerations & side effects

For the approved implant, commonly reported side effects in clinical use include nausea, headache, fatigue, skin discoloration at the implant site, and darkening of existing moles or freckles. Because the compound increases pigmentation broadly, changes to moles are a reason many clinicians recommend periodic skin monitoring.

The injectable research-market version carries additional uncertainty: it is unregulated, purity varies, and it has not been evaluated for cosmetic use by regulators. Any new, changing, or unusual skin lesion warrants evaluation by a qualified clinician. This information is educational and is not a substitute for professional medical advice.